Filter news by date Month MonthJanuaryFebruaryMarchAprilMayJuneJulyAugustSeptemberOctoberNovemberDecember Year Year2020201920182017201620152014201320122011 Apply On International Kissing Day, Galderma Shares First-of-its-Kind Phase IV Kissability Study Results Showing Both Subject and Partner Satisfaction with Restylane® Kysse Galderma Announces an Acceleration of its Growth and Expansion Plans to Support Aesthetic Providers Differin® Launches Clear90™ App, to Support People with Acne on Their Clear Skin Journey as Part of Third-Annual Retinoid Education Week Fort Worth’s Galderma, Maker of Cetaphil, Presents the 5th Annual Wonder Run 5K and Kids 1K to Benefit Children’s Skin Disease Foundation Galderma Demonstrates Robust Aesthetic Innovation Pipeline with Initiation of Seven New Clinical Studies Galderma Announces Positive Phase 2 Results for its Proprietary Liquid Formulation of an Investigational Botulinum Toxin and Approval of New State-of-the-Art Manufacturing Facility Galderma Receives FDA Approval for AKLIEF® (trifarotene) Cream, 0.005%, the First New Retinoid Molecule for the Treatment of Acne in Over 20 Years Galderma to become the world’s largest independent global dermatology company after completion of CHF 10.2 billion carve-out of Nestlé Skin Health Cetaphil® Announces Partnership with Award-Winning Actress, Rachel Brosnahan A Decade of Dysport®: Galderma Celebrates 10 Years Since FDA Approval of Dysport in the U.S. Galderma Announces U.S. Collaboration with Nespresso® Galderma Announces Formation of Women in Aesthetics Leadership Council Pagination Next page Next
On International Kissing Day, Galderma Shares First-of-its-Kind Phase IV Kissability Study Results Showing Both Subject and Partner Satisfaction with Restylane® Kysse
Differin® Launches Clear90™ App, to Support People with Acne on Their Clear Skin Journey as Part of Third-Annual Retinoid Education Week
Fort Worth’s Galderma, Maker of Cetaphil, Presents the 5th Annual Wonder Run 5K and Kids 1K to Benefit Children’s Skin Disease Foundation
Galderma Demonstrates Robust Aesthetic Innovation Pipeline with Initiation of Seven New Clinical Studies
Galderma Announces Positive Phase 2 Results for its Proprietary Liquid Formulation of an Investigational Botulinum Toxin and Approval of New State-of-the-Art Manufacturing Facility
Galderma Receives FDA Approval for AKLIEF® (trifarotene) Cream, 0.005%, the First New Retinoid Molecule for the Treatment of Acne in Over 20 Years
Galderma to become the world’s largest independent global dermatology company after completion of CHF 10.2 billion carve-out of Nestlé Skin Health
